BROKER RATINGS: Barclays and Goldman Sachs downgrade Hammerson
BROKER RATINGS: Barclays and Goldman Sachs downgrade Hammerson
Read moreWed, 18th Aug 2021 09:51
BROKER RATINGS: Barclays and Goldman Sachs downgrade Hammerson
Read moreVectura shares rise on swing to profit, GBP115 million special payout
Read more(Sharecast News) - Vectura reported a 6.9% improvement in its total revenue on Thursday, to £190.6m, driven by development services and a surge in income from royalties.
Read moreUK earnings, trading statements calendar - next 7 days
Read more(Sharecast News) - Vectura delayed the publication of its annual results after KPMG asked for more time to audit the accounts because of a staff shortage caused by Covid-19.
Read moreUK earnings, trading statements calendar - next 7 days
Read moreLONDON BROKER RATINGS SUMMARY: Deutsche Bank Ups British Land, Landsec
Read moreVectura Forecasts 2020 Earnings To Top Board Expectations
Read more(Sharecast News) - Inhaled medicines-focussed pharmaceutical company Vectura Group updated the market on its trading on Tuesday, saying it expected revenue and adjusted EBITDA for 2020 to be ahead of board expectations, following the fourth quarter approval of VR315 (US), or generic 'Advair', alongside Hikma.
Read moreUK EXECUTIVE CHANGE SUMMARY: Nutrition Firm Director Joins Tate & Lyle
Read moreVectura Says Glaxo Will Not Appeal Award In Ellipta Litigation
Read more(Sharecast News) - Vectura said on Tuesday that GlaxoSmithKline has not sought to petition the US Court of Appeals for a re-hearing in the companies' ongoing litigation over GSK's Ellipta inhalers.
Read moreLONDON MARKET CLOSE: Stocks Fall As Investors Sweat On Brexit Deal
Read moreLONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound
Read moreUK WINNERS & LOSERS SUMMARY: US Generic Advair Ok Lifts Hikma, Vectura
Read more